146 related articles for article (PubMed ID: 38633284)
1. Association Between
Young JR; Ressler JA; Mortimer JE; Schmolze D; Fitzgibbons M; Chen BT
Nucl Med Mol Imaging; 2024 May; 58(3):113-119. PubMed ID: 38633284
[TBL] [Abstract][Full Text] [Related]
2. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
7. Association of Relative Cerebral Blood Volume from Dynamic Susceptibility Contrast-Enhanced Perfusion MR with HER2 Status in Breast Cancer Brain Metastases.
Young JR; Ressler JA; Shiroishi MS; Mortimer JE; Schmolze D; Fitzgibbons M; Chen BT
Acad Radiol; 2023 Sep; 30(9):1816-1822. PubMed ID: 36549990
[TBL] [Abstract][Full Text] [Related]
8. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
10. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Histopathological Prognostic Tumor Characteristics and [
Boers J; Eisses B; Zwager MC; van Geel JJL; Bensch F; de Vries EFJ; Hospers GAP; Glaudemans AWJM; Brouwers AH; den Dekker MAM; Elias SG; Kuip EJM; van Herpen CML; Jager A; van der Veldt AAM; Oprea-Lager DE; de Vries EGE; van der Vegt B; Menke-van der Houven van Oordt WC; Schröder CP;
Diagnostics (Basel); 2024 Feb; 14(4):. PubMed ID: 38396455
[TBL] [Abstract][Full Text] [Related]
12. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
Kim JY; Lee SH; Kim S; Kang T; Bae YT
Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and molecular predictors of [
Llombart-Cussac A; Prat A; Pérez-García JM; Mateos J; Pascual T; Escrivà-de-Romani S; Stradella A; Ruiz-Borrego M; de Las Heras BB; Keyaerts M; Galvan P; Brasó-Maristany F; García-Mosquera JJ; Guiot T; Gion M; Sampayo-Cordero M; Di Cosimo S; Pérez-Escuredo J; de Frutos MA; Cortés J; Gebhart G
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38587643
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
15. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
16. Value of
de Mooij CM; Mitea C; Mottaghy FM; Smidt ML; van Nijnatten TJA
EJNMMI Res; 2021 Nov; 11(1):116. PubMed ID: 34807395
[TBL] [Abstract][Full Text] [Related]
17. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Relative Diagnostic Performance of [
Wu J; Wang Y; Liao T; Rao Z; Gong W; Ou L; Chen Y; Zhang C
Front Oncol; 2021; 11():737827. PubMed ID: 34604078
[TBL] [Abstract][Full Text] [Related]
19. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
20. Comparison of
Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
